{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,5,17]],"date-time":"2024-05-17T16:12:33Z","timestamp":1715962353700},"reference-count":31,"publisher":"Wiley","issue":"7","license":[{"start":{"date-parts":[[2008,5,6]],"date-time":"2008-05-06T00:00:00Z","timestamp":1210032000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Journal of Medical Virology"],"published-print":{"date-parts":[[2008,7]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Hepatitis A virus (HAV) is the major pathogen responsible for acute infectious hepatitis A, a disease that is prevalent worldwide. Although HAV immunization effectively prevents infection, primary immunizations must be administered at least 2 weeks prior to HAV exposure. In contrast, passive immunization with pooled human immunoglobulin (Ig) can provide immediate and rapid protection from HAV infection. Because the use of human sera\u2010derived Igs carries the risk of contamination, we sought to develop recombinant HAV\u2010neutralizing human antibodies. We prepared a combinatorial phage display library of recombinant human anti\u2010HAV antibodies from RNA extracted from the blood lymphocytes of a convalescent hepatitis A patient. Two recombinant human IgG antibodies, HAIgG16 and HAIgG78, were screened from the antibody library by their ability to bind with high affinity to purified, inactivated HAV virions. These antibodies recognized different epitopes of the HAV virion capsid, and competed with both patient sera and well\u2010characterized neutralizing mouse monoclonal antibodies. A cocktailed mixture of HAIgG16 and HAIgG78 at a 3:1 ratio was prepared to compare its combined biological activity with that conferred by each antibody individually. The cocktailed antibodies displayed a stronger neutralizing activity in vitro than that observed with either HAIgG16 and HAIgG78 alone. To determine the in vivo neutralizing abilities of these antibodies, rhesus monkeys were inoculated with cocktailed antibodies and challenged with HAV. Whereas control animals developed hepatitis A and seroconverted to the HAV antibody, animals receiving cocktailed antibodies were protected either from viral infection or from developing clinical hepatitis. These results demonstrate that recombinant human antibody preparations could be used to prevent or treat early\u2010stage HAV infection. J. Med. Virol. 80: 1171\u20131180, 2008. \u00a9 2008 Wiley\u2010Liss, Inc.<\/jats:p>","DOI":"10.1002\/jmv.21212","type":"journal-article","created":{"date-parts":[[2008,5,7]],"date-time":"2008-05-07T01:50:17Z","timestamp":1210125017000},"page":"1171-1180","source":"Crossref","is-referenced-by-count":5,"title":["Efficient neutralizing activity of cocktailed recombinant human antibodies against hepatitis a virus infection in vitro and in vivo"],"prefix":"10.1002","volume":"80","author":[{"given":"Jingyuan","family":"Cao","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shufang","family":"Meng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chuan","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yan","family":"Ji","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qingling","family":"Meng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Quanfu","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Feng","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jiandong","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shengli","family":"Bi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dexin","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mifang","family":"Liang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2008,5,6]]},"reference":[{"key":"e_1_2_1_2_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.88.18.7978"},{"key":"e_1_2_1_3_1","doi-asserted-by":"publisher","DOI":"10.1099\/0022-1317-77-10-2531"},{"key":"e_1_2_1_4_1","first-page":"118","article-title":"Human monoclonal antibody Fab fragments cloned from combinatorial libraries: Potential usefulness in prevention and\/or treatment of major human viral diseases","volume":"2","author":"Chanock RM","year":"1993","journal-title":"Infect Agents Dis"},{"key":"e_1_2_1_5_1","first-page":"303","article-title":"Expression of hepatitis A virus proteins by recombinant vaccinia virus","volume":"5","author":"Gao F","year":"1989","journal-title":"Chin J Virol"},{"key":"e_1_2_1_6_1","first-page":"735","volume-title":"Fields virology","author":"Hollinger FB","year":"1996"},{"key":"e_1_2_1_7_1","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1128\/jvi.52.2.465-473.1984","article-title":"Neutralizing monoclonal antibodies to hepatitis A virus: Partial localization of a neutralizing antigenic site","volume":"52","author":"Hughes JV","year":"1984","journal-title":"J Virol"},{"key":"e_1_2_1_8_1","doi-asserted-by":"publisher","DOI":"10.1006\/viro.1999.9813"},{"key":"e_1_2_1_9_1","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1097-0290(19980405)58:1<73::AID-BIT8>3.0.CO;2-R"},{"key":"e_1_2_1_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.virol.2003.10.014"},{"key":"e_1_2_1_11_1","doi-asserted-by":"publisher","DOI":"10.1099\/0022-1317-83-9-2091"},{"key":"e_1_2_1_12_1","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/134.1.70"},{"key":"e_1_2_1_13_1","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1128\/iai.40.2.766-772.1983","article-title":"Experimental infection of the new world owl monkey (A. trivirgatus) with hepatitis A virus","volume":"40","author":"LeDuc JW","year":"1983","journal-title":"Infect Immun"},{"key":"e_1_2_1_14_1","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/161.1.7"},{"key":"e_1_2_1_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/0042-6822(92)90758-H"},{"key":"e_1_2_1_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/0264-410X(92)90540-Z"},{"key":"e_1_2_1_17_1","doi-asserted-by":"crossref","first-page":"2829","DOI":"10.4049\/jimmunol.151.5.2829","article-title":"Rescue, expression, and analysis of a neutralizing human anti\u2010hepatitis A virus monoclonal antibody","volume":"151","author":"Lewis AP","year":"1993","journal-title":"J Immunol"},{"key":"e_1_2_1_18_1","doi-asserted-by":"publisher","DOI":"10.1006\/viro.1996.0113"},{"key":"e_1_2_1_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-1759(00)00322-7"},{"key":"e_1_2_1_20_1","doi-asserted-by":"publisher","DOI":"10.1002\/jmv.10259"},{"key":"e_1_2_1_21_1","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1128\/jcm.18.5.1237-1243.1983","article-title":"Monoclonal antibodies against hepatitis A virus","volume":"18","author":"MacGregor A","year":"1983","journal-title":"J Clin Microbiol"},{"key":"e_1_2_1_22_1","doi-asserted-by":"publisher","DOI":"10.1093\/nar\/18.17.5322"},{"key":"e_1_2_1_23_1","doi-asserted-by":"publisher","DOI":"10.1128\/CMR.19.1.63-79.2006"},{"key":"e_1_2_1_24_1","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.66.4.2208-2216.1992"},{"key":"e_1_2_1_25_1","doi-asserted-by":"publisher","DOI":"10.1016\/0264-410X(92)90572-2"},{"key":"e_1_2_1_26_1","first-page":"493","article-title":"A simple method for estimating fifty percent endpoints","volume":"27","author":"Reed LJ","year":"1938","journal-title":"Am J Hygiene"},{"key":"e_1_2_1_27_1","doi-asserted-by":"publisher","DOI":"10.1099\/0022-1317-73-6-1365"},{"key":"e_1_2_1_28_1","doi-asserted-by":"publisher","DOI":"10.1006\/viro.2001.1252"},{"key":"e_1_2_1_29_1","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.61.2.491-498.1987"},{"key":"e_1_2_1_30_1","doi-asserted-by":"publisher","DOI":"10.1016\/0016-5085(85)90462-7"},{"key":"e_1_2_1_31_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0264-410X(98)00370-3"},{"key":"e_1_2_1_32_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.89.8.3175"}],"container-title":["Journal of Medical Virology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fjmv.21212","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/jmv.21212","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,14]],"date-time":"2023-11-14T13:40:44Z","timestamp":1699969244000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/jmv.21212"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,5,6]]},"references-count":31,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2008,7]]}},"alternative-id":["10.1002\/jmv.21212"],"URL":"https:\/\/doi.org\/10.1002\/jmv.21212","archive":["Portico"],"relation":{},"ISSN":["0146-6615","1096-9071"],"issn-type":[{"value":"0146-6615","type":"print"},{"value":"1096-9071","type":"electronic"}],"subject":[],"published":{"date-parts":[[2008,5,6]]}}}